Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 5:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 734 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Migraines Clear all
Completed Phase 3 Interventional Results available

Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine

NCT05216263
View directory record Official record
Conditions
Chronic Migraine
Interventions
Atogepant
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
29
States / cities
Hoover, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Jul 21, 2026, 5:02 AM EDT
Completed Phase 1 Interventional

Study to Evaluate the PK of BMS-927711 in Patient With Migraine During Acute Migraine and Non-migraine Condition

NCT01445067
View directory record Official record
Conditions
Migraine
Interventions
BMS-927711 (CGRP Antagonist)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
4
States / cities
Glendale, California • Long Beach, California • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Jul 21, 2026, 5:02 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of AMG 301 in Migraine Prevention

NCT03238781
View directory record Official record
Conditions
Chronic Migraine or Episodic Migraine
Interventions
Placebo, AMG 301
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 60 Years
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
21
States / cities
Long Beach, California • Santa Monica, California • Boulder, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2020 · Synced Jul 21, 2026, 5:02 AM EDT
Completed Not applicable Interventional Results available

Assessment of Safety and Efficacy of Nerivio for the Migraine Prevention

NCT04828707
View directory record Official record
Conditions
Migraine
Interventions
Nerivio active device, Nerivio sham device
Device
Lead sponsor
Theranica
Industry
Eligibility
18 Years to 75 Years
Enrollment
335 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
16
States / cities
Phoenix, Arizona • Carlsbad, California • Newport Beach, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced Jul 21, 2026, 5:02 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Computer Game, Qualitative, and MEG/EEG Assessment of Serotonergic Psychedelics

NCT06624137
View directory record Official record
Conditions
OCD, Major Depressive Disorder (MDD), Alcohol Use Disorder (AUD), Healthy Volunteer, Migraine, PTSD, PTSD - Post Traumatic Stress Disorder, Addiction, Tobacco Use Disorder, Obsessive Compulsive Disorder (OCD), Opioid Use Disorder
Interventions
Serotonergic Psychedelic, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
2
States / cities
Hamden, Connecticut • West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Jul 21, 2026, 5:02 AM EDT
Completed No phase listed Observational

Patent Foramen Ovale in Children With Migraine Headaches

NCT00750594
View directory record Official record
Conditions
Migraine Headaches
Interventions
Not listed
Lead sponsor
University of Utah
Other
Eligibility
6 Years to 17 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 25, 2017 · Synced Jul 21, 2026, 5:02 AM EDT
Completed Phase 3 Interventional

To Evaluate the Safety and Efficacy of Trexima in the Acute Treatment of Migrane Headaches

NCT00434083
View directory record Official record
Conditions
Migraine Headaches
Interventions
sumatriptan, naproxen sodium
Drug
Lead sponsor
POZEN
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 11, 2007 · Synced Jul 21, 2026, 5:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single-Ascending Dose Study of AMG 333 in Healthy Subjects and Subjects With Migraines

NCT01953341
View directory record Official record
Conditions
Migraine
Interventions
AMG 333, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 55 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 8, 2014 · Synced Jul 21, 2026, 5:02 AM EDT
Completed Phase 2 Interventional

Study of Lornoxicam or Placebo for Acute Treatment of the Headache of Migraine.

NCT00293657
View directory record Official record
Conditions
Headache (Migraine)
Interventions
Lornoxicam 8 mg, Lornoxicam 16 mg, Placebo
Drug
Lead sponsor
POZEN
Industry
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Timeline
2005 – 2006
U.S. locations
23
States / cities
Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 20 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2012 · Synced Jul 21, 2026, 5:02 AM EDT
Completed Phase 3 Interventional Results available

A Study Using Botulinum Toxin Type A as Headache Prophylaxis in Adolescents With Chronic Migraine

NCT01662492
View directory record Official record
Conditions
Migraine Disorders
Interventions
Botulinum toxin type A Dose 1, Botulinum toxin type A Dose 2, Placebo (Normal Saline)
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
12 Years to 17 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
22
States / cities
Phoenix, Arizona • Fullerton, California • Oceanside, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2017 · Synced Jul 21, 2026, 5:02 AM EDT
Terminated Not applicable Interventional Results available

Spectacle Tints and Thin-Films for Migraine

NCT02720211
View directory record Official record
Conditions
Headache Migraine Chronic
Interventions
Gray tinted spectacle lenses, Thin-Film spectacle lenses
Device
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
4
States / cities
Phoenix, Arizona • Boston, Massachusetts • Great Neck, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2022 · Synced Jul 21, 2026, 5:02 AM EDT
Completed Phase 2 Interventional

An Acute Migraine Factorial Study

NCT06245902
View directory record Official record
Conditions
Migraine With or Without Aura
Interventions
Naltrexone and Acetaminophen, Naltrexone and Acetaminophen-High Dose, Naltrexone Alone (regular dose), Acetaminophen Alone, Matching Placebo
Drug
Lead sponsor
Allodynic Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
North Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 6, 2024 · Synced Jul 21, 2026, 5:02 AM EDT
Not yet recruiting No phase listed Observational Accepts healthy volunteers

Validation of the Vestibular Migraine Patient Assessment Tool and Handicap Inventory (VM-PATHI) for Adolescents

NCT07532109
View directory record Official record
Conditions
Vestibular Migraine
Interventions
Vestibular Migraine Patient Assessment Tool and Handicap Inventory (VM-PATHI)
Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
10 Years to 20 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
3
States / cities
Needham, Massachusetts • Waltham, Massachusetts • Weymouth, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Jul 21, 2026, 5:02 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Single Ascending Dose Study to Investigate the Safety and Pharmacokinetics of XC101-D13H in Healthy Adult Subjects

NCT04104399
View directory record Official record
Conditions
Migraine
Interventions
XC101-D13H, Placebo
Drug
Lead sponsor
Xoc Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 22, 2021 · Synced Jul 21, 2026, 5:02 AM EDT
Recruiting Phase 3 Interventional

A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine

NCT06616194
View directory record Official record
Conditions
Migraine
Interventions
Rimegepant, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years to 17 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
27
States / cities
Phoenix, Arizona • Long Beach, California • Aurora, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Jul 21, 2026, 5:02 AM EDT
Completed Phase 1Phase 2 Interventional

Occipital Nerve Stimulation to Treat Chronic Headaches

NCT00205894
View directory record Official record
Conditions
Headache Disorders
Interventions
bion microstimulator
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
2
States / cities
Scottsdale, Arizona • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 4, 2008 · Synced Jul 21, 2026, 5:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Psychological Assessment and Treatment of Chronic Benign Headache

NCT00018811
View directory record Official record
Conditions
Headache, Migraine, Tension Headache, Stress Headache, Vascular Headache
Interventions
Relaxation training & thermal biofeedback, Surface EMG biofeedback
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2003
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 20, 2009 · Synced Jul 21, 2026, 5:02 AM EDT
Terminated Phase 1 Interventional

Occipital Nerve Stimulation in the Treatment of Migraine

NCT01855672
View directory record Official record
Conditions
Migraine
Interventions
Stimulation of the Occipital Nerves
Device
Lead sponsor
Ethicon, Inc.
Industry
Eligibility
8 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
4
States / cities
Newington, New Hampshire • New York, New York • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2013 · Synced Jul 21, 2026, 5:02 AM EDT
Completed Phase 1 Interventional Results available

AMG 334 20160172 Pediatric Migraine PK Study.

NCT03499119
View directory record Official record
Conditions
Migraine
Interventions
AMG 334 Dose 1, AMG 334 Dose 2, AMG 334 Dose 3
Drug
Lead sponsor
Amgen
Industry
Eligibility
6 Years to 17 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
14
States / cities
Little Rock, Arkansas • Englewood, Colorado • Stamford, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated May 27, 2024 · Synced Jul 21, 2026, 5:02 AM EDT
Completed Phase 3 Interventional Results available

Atogepant for Prophylaxis of Migraine in Participants Who Failed Previous Oral Prophylactic Treatments.

NCT04740827
View directory record Official record
Conditions
Episodic Migraine
Interventions
Atogepant 60 mg, Placebo
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 80 Years
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
26
States / cities
Colton, California • Encino, California • Los Alamitos, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Jul 21, 2026, 5:02 AM EDT
Completed Phase 3 Interventional Results available

12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine

NCT03777059
View directory record Official record
Conditions
Episodic Migraine
Interventions
Atogepant, Placebo
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 80 Years
Enrollment
910 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
138
States / cities
Chandler, Arizona • Glendale, Arizona • Phoenix, Arizona + 112 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2021 · Synced Jul 21, 2026, 5:02 AM EDT
Not listed Phase 4 Interventional

Ketamine v. Ketorolac for Management of Generalized Tension Type Headache

NCT03221569
View directory record Official record
Conditions
Migraine
Interventions
Intravenous ketamine, Ketorolac, Normal saline
Drug
Lead sponsor
The Brooklyn Hospital Center
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Jul 21, 2026, 5:02 AM EDT
Not yet recruiting Not applicable Interventional

Dietary Intervention for Migraine Relief

NCT07360405
View directory record Official record
Conditions
Migraine
Interventions
Dietary training
Behavioral
Lead sponsor
American University
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Jul 21, 2026, 5:02 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

NINDS CRC Chronic Migraine Treatment Trial

NCT00772031
View directory record Official record
Conditions
Chronic Migraine
Interventions
propranolol LA, topiramate, placebo
Drug
Lead sponsor
Anne Lindblad
Industry
Eligibility
18 Years and older
Enrollment
191 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
39
States / cities
Phoenix, Arizona • Tuscon, Arizona • Chico, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2012 · Synced Jul 21, 2026, 5:02 AM EDT